Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level
Por:
Manini C, López-Fernández E, Lawrie CH, Laruelle A, Angulo JC and López JI
Publicada:
1 jun 2022
Ahead of Print:
1 abr 2022
Resumen:
Purpose of Review Intratumor heterogeneity (ITH) is an inherent characteristic of most tumors and its detection remains a key task for pathologists. However, the clinical significance of the degree of development of this feature is still poorly understood. Recent Findings A series of 28 clear cell renal cell carcinomas (CCRCC) have been exhaustively analyzed with two different sampling protocols [multisite tumor sampling (MSTS) and total sampling] to evaluate to what point the level (low vs. high) of histological ITH detected in routine practice influences tumor behavior and patients' survival. All CCRCC (n = 14) pursuing an aggressive clinical course presented low levels of ITH. A significant worse survival was detected in CCRCC with low ITH (p < 0.001). The simple quantification of the level of ITH using extensive sampling protocol may be of help in predicting tumor evolution, since all CCRCC with aggressive behavior demonstrated low levels of histological ITH.
Filiaciones:
Manini C:
Department of Pathology, San Giovanni Bosco Hospital, 10154, Turin, Italy
Department of Sciences of Public Health and Pediatrics, University of Turin, 10124, Turin, Italy
:
FISABIO Foundation, 46020, Valencia, Spain
Department of Health Sciences, European University of Valencia, 46023, Valencia, Spain
Lawrie CH:
Molecular Oncology Group, Biodonostia Research Institute, 20014, San Sebastian, Gipuzkoa, Spain
Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9BQ, UK
Basque Foundation for Science, IKERBASQUE, 48011, Bilbao, Bizkaia, Spain
Laruelle A:
Basque Foundation for Science, IKERBASQUE, 48011, Bilbao, Bizkaia, Spain
Department of Economic Analysis, University of the Basque Country (UPV/EHU), 48015, Bilbao, Spain
Angulo JC:
Clinical Department, Faculty of Medical Sciences, European University of Madrid, 28005, Madrid, Spain
Department of Urology, University Hospital of Getafe, 28907, Getafe, Madrid, Spain
López JI:
Department of Pathology, Cruces University Hospital, Plaza de Cruces S/N, 48903, Barakaldo, Bizkaia, Spain.
Biomarkers in Cancer Group, Biocruces-Bizkaia Research Institute, 48903, Barakaldo, Spain.
|